Balanced news tone
News Sentiment
AQST sentiment intelligence
Aquestive Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
45
Balanced news tone
55 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-1.4% over one week, -1.2% over four weeks, trend inactive, and near fair-value range.
Form 144 Aquestive Therapeutics For: 15 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
78/100 classification
One-week reaction
-1.4%
Price digesting
Trend fit
Trend inactive
-1.2% over four weeks
Fair value
12.6%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
8
Neutral
30
Negative
17
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Associated Press
Direct company coverage
Aquestive Therapeutics: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 20:10
- Source
- Associated Press
Market source
Direct company coverage
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2026 07:00
- Source
- GlobeNewswire
Market source
Direct company coverage
Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 31 Mar 2026 07:00
- Source
- Market source
PR Newswire
Direct company coverage
AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
- Tone
- Negative 18/100
- Event
- Regulatory and legal
- Published
- 24 Mar 2026 07:00
- Source
- PR Newswire
Investing.com
Direct company coverage
Aquestive Therapeutics CEO Barber sells $753,965 in stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- Investing.com
Quiver Quantitative
Direct company coverage
Aquestive Therapeutics Inc. (AQST) Stock Falls on Q4 2025 Earnings
- Tone
- Negative 22/100
- Event
- Earnings
- Published
- 04 Mar 2026 08:00
- Source
- Quiver Quantitative
simplywall.st
Direct company coverage
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Feb 2026 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 04 Feb 2026 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Assessing Aquestive Therapeutics (AQST) Valuation After The FDA Complete Response Letter For Anaphylm
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Feb 2026 08:00
- Source
- simplywall.st
The American Journal of Managed Care® (AJMC®)
Direct company coverage
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Feb 2026 08:00
- Source
- The American Journal of Managed Care® (AJMC®)
Reuters
Direct company coverage
US FDA declines to approve Aquestive's oral drug for allergic reactions
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 02 Feb 2026 08:00
- Source
- Reuters
Market source
Direct company coverage
Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jan 2026 08:00
- Source
- Market source
Gotrade
Direct company coverage
Aquestive Therapeutics, Inc. Common Stock AQST ) Stock Price Today & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jan 2026 01:29
- Source
- Gotrade
Seeking Alpha
Direct company coverage
Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 12 Jan 2026 08:00
- Source
- Seeking Alpha
Market source
Direct company coverage
Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2026 08:00
- Source
- Market source
simplywall.st
Direct company coverage
Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm Filing - What's Changed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jan 2026 08:00
- Source
- simplywall.st
Market source
Direct company coverage
Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jan 2026 08:00
- Source
- Market source
Quiver Quantitative
Direct company coverage
Aquestive Therapeutics Stock (AQST) Opinions on FDA Deficiency Notice | AQST Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jan 2026 08:00
- Source
- Quiver Quantitative
Market source
Direct company coverage
Breakeven On The Horizon For Aquestive Therapeutics, Inc. (NASDAQ:AQST)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jan 2026 08:00
- Source
- Market source
simplywall.st
Direct company coverage
Aquestive Therapeutics (NASDAQ:AQST) shareholders are still up 524% over 3 years despite pulling back 6.6% in the past week
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Dec 2025 08:00
- Source
- simplywall.st
Market source
Direct company coverage
Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec”
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Market source
Stocktwits
Direct company coverage
Why Aquestive Therapeutics Stock Jumped After-Hours Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Sep 2025 07:00
- Source
- Stocktwits